CHG0521 Oral Coating

PreclinicalSmall molecule

GGuangzhou University of Traditional Chinese Medicine

CHG0521 Oral Coating is one of 26 small molecule programs targeting Metastatic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MetastaticNot yet recruiting

MetastaticPreclinical

Not yet recruiting

Competition

Competitive Landscape

27 competitors in Metastatic

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

6 2

Keytruda

Merck & Co.

Phase 2

4 3

Tecentriq

Roche

Phase 2

2 4

Trodelvy

Gilead

Phase 2

1 5

Padcev

Pfizer

Phase 2

1 6

Erbitux

IImclone

Phase 2

4 7

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

2 8

Imbruvica

PPharmacyclics LLC.

Phase 2

1 9

Zejula

GGlaxo Dba Glaxosmithkline

Phase 2

1 10

JMKX001899

JJemincare

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Metastatic1 trial

CHG0521 Oral Coating in Patients with Solid Tissue Tumor/Recurrent/Metastatic TSCC

Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·N/A·NCT06609070·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CHG0521 Oral Coating. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CHG0521 Oral Coating compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CHG0521 Oral Coating. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuangzhou University of Traditional Chinese Medicine

CHG0521 Oral Coating

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Metastatic1 trial

References

Drug Info

Quick Facts

Related News